Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Toronto Dominion Bank

Toronto Dominion Bank grew its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 5.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,714 shares of the biopharmaceutical company’s stock after purchasing an additional 2,172 shares during the quarter. Toronto Dominion Bank’s holdings in Royalty Pharma were worth $1,153,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of RPRX. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of Royalty Pharma by 60.9% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 72,762 shares of the biopharmaceutical company’s stock worth $1,919,000 after acquiring an additional 27,553 shares in the last quarter. Xponance Inc. lifted its stake in shares of Royalty Pharma by 1.9% in the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock worth $836,000 after acquiring an additional 606 shares in the last quarter. Evergreen Capital Management LLC increased its holdings in Royalty Pharma by 19.8% in the second quarter. Evergreen Capital Management LLC now owns 298,317 shares of the biopharmaceutical company’s stock valued at $7,867,000 after buying an additional 49,284 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Royalty Pharma by 778.4% in the second quarter. Thrivent Financial for Lutherans now owns 174,245 shares of the biopharmaceutical company’s stock valued at $4,595,000 after buying an additional 154,408 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

RPRX has been the subject of several research analyst reports. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a report on Monday, June 3rd. Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. The Goldman Sachs Group boosted their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Royalty Pharma Stock Up 0.3 %

NASDAQ:RPRX opened at $28.29 on Tuesday. The firm has a market capitalization of $16.79 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 4.09 and a beta of 0.46. The stock has a 50 day moving average of $28.00 and a 200-day moving average of $27.89. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. The company had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the prior year, the company earned $0.85 earnings per share. Analysts predict that Royalty Pharma plc will post 4.04 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.